FTSE MIB
34.228,51 +288,76 (+0,85%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
84,12 +0,55 (+0,66%) Bitcoin EUR
59.739,04 +606,36 (+1,03%)
Zai Lab Limited (ZLAB)
Dopo ore:
| Chiusura precedente | 15,66 |
| Aperto | 15,44 |
| Denaro | 15,73 x 100 |
| Lettera | 15,78 x 100 |
| Min-Max giorno | 15,05 - 15,82 |
| Intervallo di 52 settimane | 13,48 - 39,50 |
| Volume | |
| Media Volume | 644.400 |
| Capitalizzazione | 1,601B |
| Beta (5 anni mensile) | 1,12 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,50 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 54,12 |
GlobeNewswireZai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The Breakthrough Therapy Designation for efgartigimod SC was s
- GlobeNewswire
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumorsSHANGHAI, China and CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational repotrectinib for the treatment of patients with advanced solid tum
- GlobeNewswire
Zai Lab Announces Participation in September Investor Conferences
SHANGHAI, China and CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company’s senior management team will participate in the following investor conferences in September 2023: Citi's 18th Annual BioPharma ConferencePanel Discussion: Wednesday, September 6th at 10:30 a.m. ETLocation: Boston 2023 Cantor Global Healthcare ConferenceFireside Chat: Wednesday, September 27th at 8:00 a.m. ETLocation: New York About Zai La
